Key Highlights

  • Aterian (NASDAQ:ATER) posted a third-quarter net loss of USD 2.75 million, up from USD 2.28 million a year earlier, as USD 2.91 million of income from discontinued operations cushioned the continuing loss.
  • Trademark Global took over the flagship brands in a deal completed July 17, 2026, with USD 18.0 million paid in cash, and the MidCap Facility was settled that same day.
  • The first contingent value right distribution, totalling USD 12.4 million, reached holders on October 2, 2026, which left USD 1.5 million of unrestricted cash at September 30, 2026.
  • Under a Nasdaq bid price notice dated September 2, 2026, the company must comply by March 1, 2027, and management still flags Going Concern doubt.

A Quarter Reshaped by a Brand Divestiture

Results were released on November 16, 2026 for the period ending September 30. Aterian Aterian (NASDAQ:ATER) sells home, kitchen, air quality and personal care goods chiefly through Amazon, Walmart and Target. The transaction with Trademark Global, which was completed July 17, covered Photo Paper Direct, Healing Solutions, Squatty Potty, hOmeLabs, PurSteam and Mueller Living for USD 18.0 million, subject to purchase price adjustments. With those brands now classed as discontinued operations, continuing net Revenue amounted to just USD 31 thousand, against USD 27 thousand a year earlier. The continuing loss grew to USD 5.66 million from USD 3.00 million. Discontinued income of USD 2.91 million reduced the net loss to USD 2.75 million, or USD 0.09 a share.

Where the Sale Proceeds Are Heading

Only a small share of the cash remains with the business. A contingent value right Dividend paid out on August 17, 2026 gives holders a pro rata slice of net proceeds, once Debt and deal costs are paid, a USD 1.0 million working reserve and as much as USD 6.0 million for designated liabilities come out first. That obligation was recorded at USD 12.9 million fair value, and the first USD 12.4 million went out on October 2, 2026. Aterian separately issued Preferred Shares to David E. Lazar for USD 7.0 million, leaving him with around 95.8% of the voting securities. He later sold those preferred interests on September 25, 2026, which converted into 241,861,970 common shares, reducing his position to about 3.1%.

Going Concern Doubt and a Thinner Remaining Operation

At September 30, 2026 the Balance Sheet listed USD 1.50 million of cash, USD 13.50 million of restricted cash and USD 18.05 million of total assets, compared with USD 29.57 million at December 31, 2025. Ongoing operating costs climbed to USD 4.42 million, up from USD 2.77 million, while the nine months used USD 8.48 million of cash in operations. The surviving operation centres on the Vremi and Xtava brands at limited scale, along with new ventures that await Capital yet to be raised. A Nasdaq letter dated September 2 cited a stock price under the USD 1.00 minimum bid, with a 180-day window ending March 1, 2027. There were 261,882,422 common shares outstanding as of November 13, 2026.

Where Things Stand

Substantial doubt persists, management concedes, despite the sale of the Business core for USD 18.0 million by Aterian (NASDAQ:ATER). Net proceeds largely belong to contingent value right holders, with USD 12.4 million already settled, so funds for operations are scarce. Unrestricted cash stands at USD 1.50 million, the remaining brands are modest, and the Nasdaq bid price deadline arrives on March 1, 2027. Further contingent value right payments, any fresh business transaction, possible financing and the listing result are the next things to follow.